Literature DB >> 6603336

Multiple-dose kinetic study of mefloquine in healthy male volunteers.

I Mimica, W Fry, G Eckert, D E Schwartz.   

Abstract

250 mg mefloquine was administered orally once a week for 21 consecutive weeks to 5 volunteers. Blood samples were collected just before administration of the next dose, and the unchanged drug and its metabolite, Ro 21-5104, were measured in the plasma. The mean plasma levels minima in individual subjects measured at steady state were for mefloquine between 0.56 and 1.25 micrograms/ml, and for the metabolite between 1.47 and 5.55 micrograms/ml. The corresponding metabolite to mefloquine ratios ranged between 2.3 and 8.6. The half-life of mefloquine determined at the end of the trial agreed fairly well with values measured in single dose kinetics. This suggests that induction or inhibition of the metabolizing enzymes did not occur during the period of administration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603336     DOI: 10.1159/000238195

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  14 in total

1.  Compliance of Austrian tourists with prophylactic measures.

Authors:  H Kollaritsch; G Wiedermann
Journal:  Eur J Epidemiol       Date:  1992-03       Impact factor: 8.082

2.  Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Authors:  Trevor N Johnson; Yumi Cleary; Neil Parrott; Bruno Reigner; James R Smith; Stephen Toovey
Journal:  Br J Clin Pharmacol       Date:  2018-11-05       Impact factor: 4.335

3.  Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Authors:  Rita Piedade; Stefanie Traub; Andreas Bitter; Andreas K Nüssler; José P Gil; Matthias Schwab; Oliver Burk
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

4.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

5.  Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.

Authors:  F Nosten; J Karbwang; N J White; K Na Bangchang; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 8.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 9.  Clinical features and management of poisoning due to antimalarial drugs.

Authors:  A Jaeger; P Sauder; J Kopferschmitt; F Flesch
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

10.  The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.

Authors:  J Karbwang; D Bunnag; A M Breckenridge; D J Back
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.